ABSTRACT
Anti-Ebola vaccines and nucleoside drugs:research advances Ebola virus was extremely virulent and highly transmissible and caused outbreak of severe hemorrhagic fevers with high mortality in the Africa tropical regions. Currently, Ebola epidemic raging in West Africa, antiviral vaccines and drugs have also accelerated the development process. Basing on antigen delivery methods, EBOV vaccines can be divided into three categories of technology platform, including nonreplicative viral vector-based vaccines, replicative viral vector-based vaccines and viral protein antigen-based vaccines. ChAd3-ZEBOV and VSV-EBOV are the most promising vaccines against Ebola. With the basic molecular research of Ebola virus infection deepening, polynucleotides drugs and nucleoside analogue drugs against Ebola virus are hot research topics.
ABSTRACT
Ebola vims was extremely virulent and highly transmissible and caused outbreak of severe hemorrhagic fevers with high mortality in the Africa tropical regions. Currently. Ebola epidemic raging in West Africa, antiviral vaccines and drugs have also accelerated the development process. Basing on antigen delivery methods. EBOV vaccines can be divided into three categories of technology platform, including nonreplicative viral vector-based vaccines, replicative viral vector-based vaccines and viral protein antigen-based vaccines. ChAd3-ZEBOV and VSV-EBOV are the most promising vaccines against Ebola. With the basic molecular research of Ebola virus infection deepening, polynucleotides drugs and nucleoside analogue drugs against Ebola virus are hot research topics.
ABSTRACT
The Ebola virus was identified in the year 1976 and has caused periodic outbreaks in West African countries. The disease has a case fatality rate up to 90%. Ebola has been classified as a biosafety level four pathogen and there is no currently approved vaccine or treatment for the virus. However, remarkable progress has been demonstrated by researchers in understanding the pathogenicity of the Ebola virus. Several animal models have been cultivated to develop diagnostics, vaccines and therapeutic drugs.
ABSTRACT
The Ebola virus was identified in the year 1976 and has caused periodic outbreaks in West African countries. The disease has a case fatality rate up to 90%. Ebola has been classified as a biosafety level four pathogen and there is no currently approved vaccine or treatment for the virus. However, remarkable progress has been demonstrated by researchers in understanding the pathogenicity of the Ebola virus. Several animal models have been cultivated to develop diagnostics, vaccines and therapeutic drugs.